Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer

^aPercentages may not sum to 100 because of rounding. ER = estrogen receptor; PR = progesterone receptor; NA = not applicable.
^bGrade was missing for 888 ovarian cancer patients.

^aOther genes in which PVs were found are listed in Supplementary Table 1 (available online). ER = estrogen receptor; NA = not applicable; PR = progesterone receptor; PV = pathogenic variant; VUS = variant of uncertain significance.
^bOther surgeries recorded by Surveillance Epidemiology and End Results (SEER) for ovarian cancer treatment include local tumor destruction not otherwise specified, total removal of tumor or single ovary, unilateral or bilateral salpingo-oophorectomy with or without hysterectomy, and unilateral or bilateral salpingo-oophorectomy with omentectomy (SEER codes 17, 25–28, 35–37, 50–52, 55–57).
^cMedian follow-up was 41 months (range = 1–85 months).

^aOther genes in which PVs were found are listed in Supplementary Table 1 (available online). PV = pathogenic variant; VUS = variant of uncertain significance.
^bA 2-sided χ² test was used to calculate the P values.

^aResults presented are from a single multivariable proportional hazards model for each breast cancer subtype. CI = confidence interval; ER = estrogen receptor; HR = hazard ratio; PR = progesterone receptor; PV = pathogenic variant; VUS = variant of uncertain significance.
^bOther genes in which PVs were found are listed in Supplementary Table 1 (available online).
^cNo observations for this group.

^aOther genes in which PVs were found are listed in Supplementary Table 1 (available online). CI = confidence interval; PV = pathogenic variant; VUS = variant of unknown significance.
^bMultiple imputation was used for grade because 22% of patients had missing grade data.
^cCollapsed to serous vs not serous because of smaller numbers in subgroups of nonserous histology.
^dOther surgeries recorded by Surveillance Epidemiology and End Results (SEER) for ovarian cancer treatment include local tumor destruction not otherwise specified, total removal of tumor or single ovary, unilateral or bilateral salpingo-oophorectomy with or without hysterectomy, and unilateral or bilateral salpingo-oophorectomy with omentectomy (SEER codes 17, 25–28, 35–37, 50–52, 55–57).

Authors and Disclosures

Allison W. Kurian, MD, MSc¹,*, Paul Abrahamse, MA², Irina Bondarenko, MS², Ann S. Hamilton, PhD³, Dennis Deapen, DrPH³, Scarlett L. Gomez, PhD⁴, Monica Morrow, MD⁵, Jonathan S. Berek, MD, MMSc⁶, Timothy P. Hofer, MD, MSc⁷, Steven J. Katz, MD, MPH^2,‡ and Kevin C. Ward, PhD, MPH<sup>8,‡

1</sup>Departments of Medicine and of Epidemiology & Population Health, Stanford University, Stanford, CA, USA; ²Department of Health Management and Policy, School of Public Health, Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA; ³Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; ⁴Department of Epidemiology & Biostatistics and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA; ⁵Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York City, NY, USA; ⁶Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Women's Cancer Center, Stanford University, Stanford, CA, USA; ⁷Department of Internal Medicine, University of Michigan and Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, USA and ⁸Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA

*Correspondence to
Allison W. Kurian, MD, MSc, Professor of Medicine and of Epidemiology & Population Health, Stanford University School of Medicine, HRP Redwood Building, Room T254A, 150 Governor's Lane, Stanford, CA 94305-5405, USA (e-mail: akurian@stanford.edu).

^‡These authors contributed equally to this work.

Disclosures
Research funding to her institution for an unrelated project was provided to Allison Kurian, MD, MSc, by Myriad Genetics. The authors have no conflicts of interest to declare.

Author contributions
Conceptualization: AK, SK, KW; Formal analysis: PA, IB, TH; Data curation: PA; Resources: KW, AH, SG, DD; Writing—original draft: AK, SK, KW; Writing—review and editing: AK, PA, IB, AH, DD, SG, MM, JB, TH, SK, KW; Funding acquisition: AK, SK